Gamma aminobutyric acid (GABA) type A receptors play a key role in brain inhibitory neurotransmission, and are ligand-activated chloride channels blocked by numerous convulsant ligands. Here we summarize data on binding of picrotoxin, tetrazoles, β-lactams, bicyclophosphates, butyrolactones and neurotoxic pesticides to GABA-A ionophore, and discuss functional and structural overlapping of their binding sites. The paper reviews data on convulsants' binding sensitivity to different point mutations in ionophore-lining second transmembrane domains of GABA-A subunits, and maps possible location of convulsants' sites within the chloride ionophore. We also discuss data on inhibition of glycine, glutamate, serotonin (5-HT3) and N-acetylcholine receptors by GABA-A channel blockers, and examine the applicability of this model to other homologous ionotropic receptors. Positioning various convulsant-binding sites within ionophore of GABA-A receptors, this model enables a better understanding of complex architectonics of ionotropic receptors, and may be used for developing new channel-modulating drugs.
GABA and GABA-A receptor complex
Gamma-amino butyric acid (GABA) is the primary mediator of inhibitory transmission in the mammalian central nervous system Korpi et al., 2002; Leung and Xue, 2003) . It has complex interactions with other neurotransmitter systems and acts through ionotropic A and metabotropic B type receptors (Martin and Dunn, 2002; Atack, 2003 Atack, ,2005 . Both receptors are a target for many endogenous and exogenous modulators that regulate normal and pathological brain mechanisms -sleep, memory, epilepsy and emotions (Kalueff and Nutt, 1997 GABA-A receptors are crucial for controlling brain excitability, and represent ligand-gated ion channels composed of five subunits (belonging to eight families: α1-6, β1-3, γ1-3, δ, ε, π, θ and ρ1-3) around the ionophore (Baumann et (Table 1; Maksay, 1996) , and also block other non-GABAergic ionotropic receptors (Table 3 Although mechanisms of action of non-ionophore modulators of GABA-A receptors have been extensively studied, the effector part of the receptor -its ionophore -is much less understood. It has long been thought that various convulsants inhibit ion influx by physically plugging ionophore (rev.: Petter et al., 1999; Behrends, 2000) when bound in different positions to a common "convulsant" binding pocket. Described in the literature as picrotoxin(in) site or receptor (Holland et (Felix, 2000) and facilitate the development of novel selective ionophore-targeting drugs (Eldefrawi and Eldefrawi, 1987; Bloomquist, 2003) .
Since channel ligands are thought to bind to heterogeneous binding sites within ionophore, the important question is the positioning of these binding sites within the ionophore and relative to each other. Point mutagenesis data may give an important information on which TM2 residues may be critical for binding of different ligands. For example, a common critical residue for two convulsants implies overlapping of their binding sites, whereas different critical residues for these ligands suggests their distinct binding sites. As recent extensive data provides important insights into functional properties of ionophore receptors (Ffrench-Constant et al., 1993;Gurley et al., 1995;Perret et al., 1999), we will systematically evaluate the available literature on pharmacology and mutagenesis of GABA-A and other homologous ionotropic receptors, in order to develop a model of ionophore binding sites for different classes of GABAactive ligands. Table 1 summarizes known physiological and pharmacological properties of traditional GABA-A ionophore blockers. Table 2 shows point mutagenesis data for major GABA-A chemoconvulsants, outlining critical residues for each class of ionophore ligands. Table 3 describes the ability of ionophore blockers to inhibit other ionotropic (glycine, glutamate, serotonin 5-HT3 and N-acetylcholine) receptors. Fig. 1 shows a model of GABA-A ionophore, developed based on data in Tables 1-3 .
Ionophore sites and their ligands

Picrotoxin site
As picrotoxin effectively inhibits chloride influx in GABA-A (Newland and Cull-Candy, 1992) and other ionotropic receptors (Table 3) , it represents a universal "reference" channel blocker Olsen, 2006) with whom other ligands may be compared (Table 1) . While the exact location of picrotoxin binding to ionophore is still unknown (Huang et al., 2001) , its sensitivity to mutations in residues 2/3 and 6 of TM2 suggests that the site contains residues 2-6 ( Table 2 ; Buhr et al., 2001 ). In line with this, Zhorov and Bregestovski (2000) suggested that picrotoxin penetrates deep inside the ionophore pore, binding with its hydrophobic moiety to residue 2 of TM2 (close to the pore) and forming hydrogen bounds with residue 6 in the middle of TM2. Importantly, while amino acid composition of residue 2 is variable in different ionotropic receptors, the composition of residue 6 is highly conservative, implying that it is crucial for picrotoxin binding to ionophore, and most likely representing the epicenter of its binding pocket (Fig. 1) .
While residue 15 is critical for picrotoxin binding to glycine receptors, its mutation in GABA-A receptors inhibited (but not abolished) use-dependent ionophore block by picrotoxin, suggesting that this residue may be important for interplay between GABA and picrotoxin binding sites (Dibas et al., 2002) . Other studies implicate residues 9 and 15 in the regulation of channel properties, such as desensitization, stabilization of open states and gating (Findlay et al., 2001; Scheller and Forman, 2002) . Taken together, this indirectly supports the possibility of a second "modulatory" (allosteric) binding site of picrotoxin including residues 15-19. In line with this, residue 17 is important for picrotoxin modulation of GABA-A receptors (Horenstein et al., 2001 ). The hypothesis of an additional allosteric picrotoxin site (Fig. 1) is also indirectly supported by recent data (Mortensen et al., 2003) showing that potency of picrotoxin binding is highly dependent on the level of spontaneous activity of GABA-A receptors.
PTZ (tetrazole) site
Although early studies hypothesized PTZ binding to benzodiazepine site of GABA-A receptors, similarity to picrotoxin (in terms or molecular structure, use-dependent voltageindependent action and displacement of TBPS) prompted its activity at ionophore "convulsant" site (Table 1 ; Dibas and Dillon, 2000) . Some butyrolactones and PTZ share stereo-structural similarity and synergetically affected TBPS binding (Maksay et al., 1994) . This, and the ability of selected butyrolactones to inhibit binding of other cage convulsants -picrotoxin, PTZ or bicyclophosphates (rev.: Dibas and Dillon, 2000;Huang et al., 2001), supports the idea that all these binding sites overlap. Finally, similar sensitivity of picrotoxin and PTZ binding to some mutations in TM2 further confirms this notion .
However, there are several distinctions between picrotoxin and PTZ actions, including different affinity and dynamics of association with ionophore and Cl-current inhibition (Huang et al., 2001 ). Another dissimilarity is the lack of complex (competitive + non-competitive) effects in PTZ (Table 1) . TM2 residues 1, 2 and 3 of β-subunits of GABA-A receptors were important to form TBPS binding site in chimeric receptors, implying that these residues form the TBPS binding pocket (Jursky et al., 2000) (Fig. 1) .
Butyrolactone site
Earlier reports on competitive inhibition of TBPS binding by convulsant butyrolactones suggested that they bind to a common TBPS/picrotoxin "convulsant" ionophore site (Holland et al., 1991 (Holland et al., ,1995 Mathews et al., 1996; Canney et al., 1998; Gonzales et al., 2003) . This is also in line with similar chemical structures of these ligands (e.g., picrotoxin molecule contains a butyrolactone ring) (Williams et al., 1997). Likewise, butyrolactones share similar physiological and pharmacological mechanisms of action with PTZ (Maksay et al., 1994) , and are able to allosterically modulate TBPS binding (Holland et al., 1990 (Holland et al., ,1991 (Holland et al., ,1993 . Collectively, this implies that picrotoxin, PTZ, TBPS and butyrolactones may bind to overlapping ionophore binding sites (Fig. 1) .
Although butyrolactone binding site is not yet identified (Gonzales et al., 2003) , the sensitivity of butyrolactone binding to point mutations in residue 6 (Huang et al., 2001) indicates its location within a common binding area for these convulsants. Since mutations affecting picrotoxin binding also affect that of butyrolactones (Huang et al., 2001) , it is indeed likely that binding sites for picrotoxin and butyrolactones significantly overlap (Fig. 1) . In contrast, other studies have demonstrated anticonvulsant effects of some butyrolactones, suggesting either antagonism of the picrotoxin receptor, or a second positive (modulatory) "lactone" site (Holland et al., 1991 (Holland et al., ,1993 (Holland et al., ,1995 
Penicillin and lactam site(s)
Despite early studies (implying action via benzodiazepine site; Shiraishi et al., 1993) , later data demonstrated binding of penicillin and other β-lactams to an ionophore site, with a physical blockage of GABA-A channel (Twyman et (Kalueff, 2002) confirms that penicillin, like other ionophore ligands, acts via a common convulsant binding site. Sensitivity of penicillin binding to mutations in TM2 residue 6 (Table 2) indicates that it may be a common site for picrotoxin, PTZ and penicillin (Fig. 1) .
However, the fact that such mutation completely abolished picrotoxin binding, but only reduced penicillin binding (Sugimoto et al., 2002) , suggests that residue 6 may be on a border of penicillin binding pocket, as suggested in Fig. 1 . Insensitivity of penicillin (but not picrotoxin) binding to a point mutation in residue 9 indicates that this residue is not a critical element of penicillin binding site, and is most likely located outside the penicillin site (Tierney et al., 1996; Lindquist et al., 2004) . Given partial effects of residue 6 mutations on penicillin binding, this indirectly suggests that penicillin binding site may be located below residue 6 of TM2 (Fig. 1) .
Notably, other β-lactams, such as cephalosporines and penems, are known as competitive voltage-independent inhibitors of GABA-A ionophore, strikingly dissimilar to noncompetitive voltage-dependent action of penicillin (Fujimoto et (Thompson et al., 1990) , suggest that binding sites of these ligands are overlapping but not identical. Sensitivity of some NP-mediated effects to point mutation in residue 2 (Edwards and Lees, 1997) ( Table 2 ) suggests the location of NP site(s) close to this residue (Fig. 1) , rather than to residue 6. Positioning bicyclophosphate site close to NP binding site in this model is also in line with numerous above-mentioned data on overlapping pharmacological mechanisms of their action. (Fig. 1 ) be generally applied to other ionophore channels? While mounting neurogenetic data generally supports this notion, it also reveals some interesting receptor-specific differences.
Non-GABA-A receptors
For example, residues 2, 6, 15 and 19 of TM2-domain of glycine receptor β-subunits are critical determinants for picrotoxin binding, whereas residue 6 is important for picrotoxin binding to glutamate and serotonin 5-HT3 receptors, although reducing but not abolishing picrotoxin sensitivity in the latter (Lynch et There are other examples of receptor-specific differences in ionophore binding of convulsant ligands. For instance, in addition to GABA-A receptors, NP also inhibit glycine receptors (Table 3) , supporting common mechanism of their action at ion channels . While NP lindane was equally effective in blocking both receptors, endosulphan and dieldrin were more active at GABA-A channels ; also see GABA-A-selectivity for another related compound BIDN (Hamon et al., 1998) . Likewise, TBPS binds to GABA-A receptors but shows much weaker binding to invertebrate GABA receptors . 
Concluding remarks
Mounting data evidences that ionophore binding sites of GABA-A and other ionotropic receptors demonstrate sufficient homology and show heterogeneous overlapping binding sites for different convulsant ligands (Fig. 1) . Ligand-binding area of ionophore can be considered as a "big picrotoxin binding pocket", representing a conservative basis for clustering sites of other channel ligands. The ability of some mutant channels to be picrotoxin-resistant and yet sensitive to other similar ligands (e.g., data for penicillin in Tierney et al., 1996) suggests a relative autonomy of ionophore blockage by different ligands. Moreover, many classes of convulsant drugs discussed here have been suggested to have dual mechanisms of ionophore action, including both inhibitory and stimulatory effects (e.g., Williams et al., 1997 (butyrolactones); Dibas and Dillon, 2000 (PTZ); Kalueff, 2002 (penicillin) ). In line with this, Lynch et al. (1995) have shown that a single mutation in glycine receptor may convert picrotoxin from antagonist into allosteric potentiator. Given similarity of various ionophore receptors, it is possible to expect that similar phenomenon may exist for other receptors, including GABA-A.
Finally, it is possible to assume that GABA-A ionophore binding sites may have complex 3D architectonics, determining the accessibility for, and interactions with, various channel convulsants. Clearly, an in-depth analysis of 3D structures of GABA-A receptor channels may improve the present ionophore model (Fig. 1) and help clarify the impact of individual TM2 point mutations on binding of different channel ligands. Moreover, in addition to ligand binding, the effects on channel functions may be related transduction mechanisms (Miyazawa et al., 2003; Unwin, 2005) . Recent homology 3D models of receptor channels (Miyazawa et al., 2003; Maksay, 2005; Reeves et al., 2005) , based on the electron microscopic structures of the nicotinic receptor channel (Unwin, 1995 (Unwin, ,2003 (Unwin, ,2005 , may be a useful approach to further modeling of GABA-A receptor ionophore.
In conclusion, although the model of ionophore suggested here (Fig. 1) needs further sophistication and elaboration, it paves the way to reconstructing ionophore binding pockets in GABA-A and other receptors, based on data from neurogenetics and neurochemistry. Understanding how different binding sites may be located relative to each other would help to design new selective ligands that will target several overlapping sites or bind simultaneously to several distinct neighboring sites. Based on modulation of "ionophore" binding sites, this may lead to creation of novel classes of selective GABA-ergic channel-active neurotropic drugs (also see Lynch et al., 1995; Dawson et al., 2000) . TM2 residues are conventionally numbered 1′-20′ from the N-terminal bottom to the Cterminal extracellular end of the helix (see Olsen, 2006 fore details). P -picrotoxin(in), BPH -bicyclophosphates, BL -butyrolactones, PTZ -pentylenetetrazole, PC -penicillin, LAother lactam antibiotics, NP -neurotoxic pesticides, P1 -"main" picrotoxin binding site, P2 -hypothetical second "allosteric" picrotoxin site. Table 1 Comparative analysis of pharmacological properties of traditional GABA-A ionophore blockers (+ present, − Table 2 Mutagenesis-based data on critical residues for binding of selected ionophore ligands to TM2 domains of GABA-A receptor subunits (legend as in Fig. 1 ). 
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